Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Figitumumab plus exemestane versus exemestane alone in first-line hormone receptor-positive advanced breast cancer
2006-005573-21Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Figitumumab + exemestane with Exemestane alone (2 arms). Primary endpoint: Progression-free survival. Started Dec 2006; status: completed.
02
Drugs
figitumumabexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-005573-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005573-21.